Eisai Inc.
Clinical trials sponsored by Eisai Inc., explained in plain language.
A pharmaceutical company focused on neurology and oncology, subsidiary of Eisai Co., Ltd.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new drug play nice with common medicines? a trial investigates Results expected Nov 2026 (estimated)
- Double attack on Alzheimer's: new drug combo targets tau and amyloid Results expected Dec 2026 (estimated)
- Mining medical claims: a smarter way to spot Alzheimer's complications? Results expected Dec 2026 (estimated)
- New pill aims to keep narcolepsy patients awake and safe Results expected Feb 2027 (estimated)
- New drug combo shows promise for Hard-to-Treat cancers Results expected Mar 2027 (estimated)
-
Can a new pill change the Brain's activity in early Alzheimer's?
Disease control Not yet recruitingThis early-stage trial is testing an experimental oral drug called E2511 in people with early Alzheimer's disease, including those with mild cognitive impairment or mild dementia. The study aims to see if E2511 affects a specific brain signal measured by PET scans, and to check i…
Phase 1 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new drug play nice with common medicines? a trial investigates
Knowledge-focused Not yet recruitingThis early-phase trial in healthy adults asks whether the experimental oral drug E2086 changes how the body processes several common medications, including an antifungal, a seizure drug, a sedative, a cough suppressant, an antidepressant, and birth control pills. Participants rec…
Phase 1 • Sponsor: Eisai Inc. • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC